Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte S p H 7.4 is an isotonic crystalloid solution that expands intravascular volume and replaces extracellular fluid losses. It provides electrolytes (sodium, chloride, potassium, magnesium, acetate, gluconate) to maintain acid-base balance and osmotic pressure. Acetate and gluconate are metabolized to bicarbonate, providing alkalinizing effect.
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
FDA-approved: Replacement of extracellular fluid losses in patients who require fluid resuscitation or maintenance, particularly in metabolic acidosis or mild to moderate acid-base disturbances.,Off-label: Not commonly used off-label; may be used in specific electrolyte imbalances or perioperative settings where balanced crystalloid is preferred.
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
Intravenous infusion; dose depends on fluid and electrolyte needs, typically 500-3000 m L/24 hours for adults.
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
Not applicable (components are endogenous substances; half-life reflects renal clearance and volume status, typically 2-4 hours for sodium and chloride in euvolemic patients).
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Acetate and gluconate are metabolized primarily in the liver and peripheral tissues to bicarbonate ions. Electrolytes are excreted or reabsorbed via renal mechanisms.
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Renal: 100% (electrolytes and buffer components are excreted unchanged by the kidneys; no biliary or fecal elimination).
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
0% (electrolytes and buffer components are not protein-bound; free in plasma).
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Sodium: 0.15-0.3 L/kg (extracellular fluid space); Chloride: similar; Bicarbonate precursor (acetate/gluconate): distributed in total body water (~0.6 L/kg).
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Intravenous: 100% (directly administered into bloodstream); not applicable to other routes.
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
No specific dosage adjustment; use with caution in severe renal impairment due to risk of electrolyte imbalances and fluid overload.
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
No specific dosage adjustment; monitor for electrolyte disturbances and fluid overload.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
Weight-based: 100-150 m L/kg/24 hours for maintenance; adjust based on clinical condition and electrolyte requirements.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Use with caution due to increased risk of fluid overload and electrolyte imbalances; start at lower end of dosing range and monitor closely.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
No FDA black box warning.
None
Use with caution in patients with congestive heart failure, severe renal impairment, hyponatremia, hyperkalemia, hypermagnesemia, or conditions predisposing to fluid overload.,May cause fluid and/or solute overload, pulmonary edema, or electrolyte disturbances.,Monitor serum electrolytes, fluid balance, and acid-base status during prolonged therapy.
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Hypersensitivity to any component.,Severe hyperkalemia or severe hypernatremia.,Patients with significant fluid overload or severe metabolic alkalosis.,Concurrent use with products containing calcium (risk of precipitation in IV line, though not directly contraindicated with this product, but caution).
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
No known food interactions. However, oral intake may be restricted or modified based on underlying condition (e.g., bowel rest, NPO status).
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
Isolyte S p H 7.4 is a balanced electrolyte solution with no known teratogenic effects in humans. No fetal risks are identified in any trimester when used appropriately for fluid and electrolyte replacement.
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
Isolyte S p H 7.4 constituents are normal components of body fluids and breast milk. No specific M/P ratio is available; however, there is no expected risk to the nursing infant when the solution is used as indicated.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
Pregnancy may alter fluid and electrolyte requirements due to increased plasma volume and glomerular filtration rate. Dosing should be individualized based on maternal status; no fixed dose adjustment is necessary, but careful monitoring of volume status is recommended.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
ISOLYTE S p H 7.4 is a balanced isotonic crystalloid solution containing multiple electrolytes (sodium, potassium, magnesium, calcium, acetate, gluconate) and is buffered to p H 7.4. It is indicated for use as a replacement fluid in extracellular volume depletion (e.g., dehydration, burns, surgery) and for maintenance fluid therapy. Avoid use in patients with hyperkalemia, hypercalcemia, or severe metabolic alkalosis. The acetate and gluconate act as bicarbonate precursors, making it suitable for correcting mild metabolic acidosis. In patients with renal impairment, monitor electrolytes closely due to risk of accumulation. Do not confuse with ISOLYTE S without p H adjustment (which may have different buffer composition).
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
This solution is given intravenously to replace lost fluids and electrolytes.,Tell your healthcare provider if you have kidney disease, heart disease, or any electrolyte imbalances.,Report any signs of fluid overload, such as shortness of breath, swelling in ankles or feet, or rapid weight gain.,Do not drive or operate heavy machinery until you know how this medication affects you.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep all appointments for blood tests to monitor electrolyte levels.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE S PH 7.4 IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte S p H 7.4 is an isotonic crystalloid solution that expands intravascular volume and replaces extracellular fluid losses. It provides electrolytes (sodium, chloride, potassium, magnesium, acetate, gluconate) to maintain acid-base balance and osmotic pressure. Acetate and gluconate are metabolized to bicarbonate, providing alkalinizing effect.. ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE S PH 7.4 IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE S PH 7.4 IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte needs, typically 500-3000 m L/24 hours for adults.. The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE S PH 7.4 IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE S PH 7.4 IN PLASTIC CONTAINER is classified as Category C. Isolyte S pH 7.4 is a balanced electrolyte solution with no known teratogenic effects in humans. No fetal risks are identified in any trimester when used appropriately for fluid an. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.